Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 18

1.

Preventing phosphorylation of dystroglycan ameliorates the dystrophic phenotype in mdx mouse.

Miller G, Moore CJ, Terry R, La Riviere T, Mitchell A, Piggott R, Dear TN, Wells DJ, Winder SJ.

Hum Mol Genet. 2012 Oct 15;21(20):4508-20. Epub 2012 Jul 18.

PMID:
22810924
2.

Functional characteristics of dystrophic skeletal muscle: insights from animal models.

Watchko JF, O'Day TL, Hoffman EP.

J Appl Physiol (1985). 2002 Aug;93(2):407-17. Review.

3.

Genetic Engineering of Dystroglycan in Animal Models of Muscular Dystrophy.

Sciandra F, Bigotti MG, Giardina B, Bozzi M, Brancaccio A.

Biomed Res Int. 2015;2015:635792. doi: 10.1155/2015/635792. Epub 2015 Aug 24. Review.

4.

Muscular dystrophies involving the dystrophin-glycoprotein complex: an overview of current mouse models.

Durbeej M, Campbell KP.

Curr Opin Genet Dev. 2002 Jun;12(3):349-61. Review.

PMID:
12076680
5.

How does dystrophin deficiency lead to muscle degeneration?--evidence from the mdx mouse.

McArdle A, Edwards RH, Jackson MJ.

Neuromuscul Disord. 1995 Nov;5(6):445-56. Review.

PMID:
8580726
6.
7.

Dystrophin-glycoprotein complex: its role in the molecular pathogenesis of muscular dystrophies.

Matsumura K, Campbell KP.

Muscle Nerve. 1994 Jan;17(1):2-15. Review.

PMID:
8264699
8.

The role of dystroglycan, a novel receptor of laminin and agrin, in cell differentiation.

Matsumura K, Yamada H, Saito F, Sunada Y, Shimizu T.

Histol Histopathol. 1997 Jan;12(1):195-203. Review.

PMID:
9046055
9.

Dystroglycan and muscular dystrophies related to the dystrophin-glycoprotein complex.

Sciandra F, Bozzi M, Bianchi M, Pavoni E, Giardina B, Brancaccio A.

Ann Ist Super Sanita. 2003;39(2):173-81. Review.

10.

Pharmacological control of cellular calcium handling in dystrophic skeletal muscle.

Ruegg UT, Nicolas-Métral V, Challet C, Bernard-Hélary K, Dorchies OM, Wagner S, Buetler TM.

Neuromuscul Disord. 2002 Oct;12 Suppl 1:S155-61. Review.

PMID:
12206810
11.

What do mouse models of muscular dystrophy tell us about the DAPC and its components?

Whitmore C, Morgan J.

Int J Exp Pathol. 2014 Dec;95(6):365-77. doi: 10.1111/iep.12095. Epub 2014 Sep 30. Review.

12.

Role of gelatinases in pathological and physiological processes involving the dystrophin-glycoprotein complex.

Bozzi M, Sciandra F, Brancaccio A.

Matrix Biol. 2015 May-Jul;44-46:130-7. doi: 10.1016/j.matbio.2015.02.005. Epub 2015 Feb 17. Review.

13.
14.

Exacerbation of pathology by oxidative stress in respiratory and locomotor muscles with Duchenne muscular dystrophy.

Lawler JM.

J Physiol. 2011 May 1;589(Pt 9):2161-70. doi: 10.1113/jphysiol.2011.207456. Epub 2011 Mar 8. Review.

15.

Finding the sweet spot: assembly and glycosylation of the dystrophin-associated glycoprotein complex.

Townsend D.

Anat Rec (Hoboken). 2014 Sep;297(9):1694-705. doi: 10.1002/ar.22974. Review.

16.

Angiogenesis as a novel therapeutic strategy for Duchenne muscular dystrophy through decreased ischemia and increased satellite cells.

Shimizu-Motohashi Y, Asakura A.

Front Physiol. 2014 Feb 18;5:50. doi: 10.3389/fphys.2014.00050. eCollection 2014. Review.

17.

SIRT1: A Novel Target for the Treatment of Muscular Dystrophies.

Kuno A, Horio Y.

Oxid Med Cell Longev. 2016;2016:6714686. doi: 10.1155/2016/6714686. Epub 2016 Mar 17. Review.

18.

Mdx mouse as therapeutic model system: development and implementation of phenotypic monitoring.

Hudecki MS, Pollina CM.

Adv Exp Med Biol. 1990;280:251-63; discussion 263-5. Review. No abstract available.

PMID:
2248146

Supplemental Content

Support Center